Engage Bio
AcquiredPotent, durable, and redosable non-viral genetic medicines
What it does
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. In 2026 Engage was acquired by Eli Lilly.
Next to it in Healthcare and bio · Non-viral genetic medicine platform
- NirvaY Combinator W21
The lifestyle medicine layer for clinicians.
- Haplotype LabsY Combinator W24
Personalized prevention using genetics and AI
- Granza BioY Combinator W24
Building programmable therapeutics for the immune system
- OpenBiomeY Combinator W20
A nonprofit stool bank enabling access to fecal transplants.
- 54GeneY Combinator W19
Precision medicine for Africans and the global population
- Circadian OSSOSV SOSV IndieBio NY 2025 H2
Hacking the Circadian Operating System
- AmplicorePlug and Play PnP 2025
Amplicore develops regenerative injectable therapeutics for musculoskeletal disorders, aiming to restore mobility and reduce pain.
- Scioto BiosciencesPlug and Play PnP 2025
Scioto is a preclinical stage company developing innovative therapies devoted to having a transformative impact.